Physician profile
Michael C Scharf
NPI 1609868744
$4,501.82
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,386 · 2020: $143 · 2021: $250 · 2022: $736 · 2023: $626 · 2024: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,256.61 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $600.09 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $506.03 | 2019-2022 | |
| Glaxosmithkline, LLC. | $392.19 | 2019-2023 | Arexvy, Shingrix |
| Amgen INC. | $335.83 | 2019-2020 | |
| Novo Nordisk INC | $196.54 | 2019 | |
| Daiichi Sankyo INC. | $137.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $131.26 | 2019 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $115.51 | 2019 | |
| Pfizer INC. | $114.21 | 2019 | |
| Lilly USA, LLC | $113.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.68 | 2019-2020 | |
| Astellas Pharma US INC | $82.93 | 2019-2020 | |
| Amarin Pharma, INC. | $54.64 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $31.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.56 | 2019 | |
| Allergan, INC. | $17.13 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.16 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.31 | 2019 | |
| Currax Pharmaceuticals LLC | $11.13 | 2019 | |
| Sanofi Pasteur INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.